Investors

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

NASDAQ: SNDX
$ 7.18 +0.19 (2.72%)
Day High: 7.23
Day Low:  6.31
Volume:    83,622
1:33 PM ET
01.23.17

Delayed ~20 min., by eSignal.

Press Releases


Events & Presentations